Ospemifene;CS-1039;Fc-1271a;Ccris 9205;Ospemifene >Unii-B0p231ilbk;2-(4-(4-chloro-1;Ospemifene FC-1271a;The department of pp meters;2-diphenyl-but-1-enyl)phenoxy)ethanol
2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol C화학적 특성, 용도, 생산
개요
In February 2013, the US FDA approved ospemifene (also referred to as FC1271a), for the treatment ofmoderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due tomenopause. It is estimated that there are 150 million postmenopausal women worldwide with 40–70% suffering from VVA. Ospemifene is a selective estrogen receptor (ER) modulator (SERM) and the first nonhormonal, nonestrogen for the treatment of moderate to severe dyspareunia in women with menopausal VVA. It binds to ERα (IC50～800 nM) and ERβ (IC50～1600 nM) with tissue-specific estrogenic agonist/antagonist effects. Treatment with ospemifene increases the thickness of the vaginal tissue thereby decreasing fragility of the tissue and reducing potential for pain during sexual intercourse.
용도
Treatment of vaginal atrophy, osteoporosis, and vasomotor symptoms.
정의
ChEBI: An organochlorine compound that is a selective estrogen receptor modulator; used for treatment of dyspareunia.
Clinical Use
Ospemifene is a SERM that is currently in Phase II/III clinical trials for the treatment of postmenopausal
osteoporosis and urogenital atrophy. It is a known metabolite of toremifene, a triphenylethylene
derivative used to treat breast cancer.Ospemifene has been shown to have beneficial effects on the bone
without significant estrogen-related side effects. The beneficial effect observed on bone stems from this
agent's ability to increase osteoblast proliferation and, as a result, to enhance bone mineralization as well as
bone formation. Unlike tamoxifen, ospemifene does not induce osteocyte apoptosis.
2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol 준비 용품 및 원자재
원자재
준비 용품
2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol 공급 업체
